VEGFA and colorectal carcinoma: Thus far, the benefit of combined VEGFA and immune checkpoint inhibition is seen in tumors that respond to single agent anti-VEGFA therapy such as HCC, RCC, CRC, NSCLC, and gynecologic tumors (Table 1).